Clopidogrel used for
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Clopidogrel: Uses and Clinical Applications
Introduction to Clopidogrel
Clopidogrel is an antiplatelet medication primarily used to prevent atherothrombotic events such as myocardial infarction, ischemic stroke, and vascular death in patients with atherosclerosis. It functions as an ADP receptor antagonist, inhibiting platelet aggregation and thus reducing the risk of clot formation.
Clopidogrel in Acute Coronary Syndromes (ACS)
Dual Antiplatelet Therapy (DAPT)
Clopidogrel is often used in combination with aspirin as part of dual antiplatelet therapy (DAPT) for the treatment and secondary prevention of acute coronary syndromes (ACS). The combination has been shown to be more effective than aspirin alone in reducing the risk of cardiovascular events, although it is associated with an increased risk of bleeding . The CURE trial demonstrated that clopidogrel plus aspirin significantly reduced the composite outcome of death from cardiovascular causes, non-fatal myocardial infarction, or stroke in patients with non-ST-segment elevation ACS.
Comparison with Newer P2Y12 Inhibitors
While newer P2Y12 inhibitors like prasugrel and ticagrelor have shown greater efficacy in reducing ischemic events compared to clopidogrel, they also come with a higher risk of bleeding. Therefore, clopidogrel remains a valuable option, especially in patients who may not tolerate the newer agents well.
Clopidogrel in Stroke and Transient Ischemic Attack (TIA)
Secondary Prevention
Clopidogrel is also used for secondary prevention in patients who have experienced a minor ischemic stroke or transient ischemic attack (TIA). Studies have shown that short-term DAPT with clopidogrel and aspirin for 21-28 days, followed by clopidogrel monotherapy, is effective in reducing the risk of major ischemic events . The CHANCE and POINT trials confirmed that the benefit of DAPT is most significant within the first 21 days after a minor stroke or high-risk TIA.
Clopidogrel in Peripheral Artery Disease (PAD)
Clopidogrel is indicated for the reduction of atherosclerotic events in patients with established peripheral arterial disease. It has been shown to be more effective than aspirin in preventing vascular events in this patient population.
Clopidogrel in Neurointerventional Procedures
Clopidogrel is routinely used to decrease ischemic complications during neurointerventional procedures, such as the treatment of unruptured intracranial aneurysms. However, its efficacy can be limited by antiplatelet resistance. Studies have shown that prasugrel may be more effective in reducing ischemic events with an acceptable rate of hemorrhagic complications compared to clopidogrel .
Clopidogrel Resistance and High On-Treatment Platelet Reactivity
Clopidogrel resistance, or high on-treatment platelet reactivity, is a phenomenon where patients exhibit a reduced response to clopidogrel, limiting its efficacy. Factors contributing to this resistance include genetic polymorphisms, concomitant use of other drugs, and certain vascular risk factors like diabetes. This resistance negatively impacts the clinical course of stroke and increases the risk of recurrent vascular events.
Clopidogrel in Combination with Anticancer Drugs
Recent studies have explored the use of clopidogrel in combination with anticancer drugs. While clopidogrel has shown potential in increasing the antitumor and antimetastatic activity of certain chemotherapeutics, it may also decrease the efficacy of others. Therefore, the use of clopidogrel in patients undergoing chemotherapy should be carefully evaluated.
Conclusion
Clopidogrel is a versatile antiplatelet agent used in various clinical settings, including ACS, stroke, TIA, and PAD. While newer P2Y12 inhibitors offer greater efficacy, clopidogrel remains a valuable option due to its balance of efficacy and safety. Understanding the nuances of clopidogrel resistance and its interactions with other medications is crucial for optimizing patient outcomes.
Sources and full results
Most relevant research papers on this topic